Evidence map›Paper›PMID 29527019›Full record

ReviewIndian journal of dermatology

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

Kiran Godse, Abhishek De, Vijay Zawar, Bela Shah, Mukesh Girdhar, Murlidhar Rajagopalan, D S Krupashankar

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Indian journal of dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Acupuncture and Related Therapies for Chronic Urticaria: A Critical Overview of Systematic Reviews.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Leukotriene Antagonists in Dermatology.Indian journal of dermatology
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Kiran GodseDepartment of Dermatology, D Y Patil Hospital, Navi Mumbai, Maharastra, India.
Abhishek DeDepartment of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India.
Vijay ZawarDepartment of Dermatology, Skin Diseases Center, Nashik, India.
Bela ShahDepartment of Dermatology, BJ Medical College, Ahmedabad, Gujarat, India.
Mukesh GirdharDepartment of Dermatology, Max Super Speciality Hospital, New Delhi, India.
Murlidhar RajagopalanDepartment of Dermatology, Apollo Hospital, Chennai, Tamil Nadu, India.
D S KrupashankarDepartment of Dermatology, Krupa Shankar Skin Care Center, Mallige Hospital, Bengaluru, Karnataka, India.
Apollo Hospitals · INB.J. Medical College · INCalcutta National Medical College and Hospital · INMax Super Speciality Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article is developed by the Skin Allergy Research Society of India for an updated evidence-based consensus statement for the management of urticaria, with a special reference to the Indian context. This guideline includes updated definition, causes, classification, and management of urticaria. Urticaria has a profound impact on the quality of life and causes immense distress to patients, necessitating effective treatment. One approach to manage urticaria is by identification and elimination of the underlying cause(s) and/or eliciting trigger(s) while the second one is by treatment for providing symptomatic relief. This guideline recommends the use of second-generation nonsedating H1-antihistamines as the first-line treatment. The dose can be increased up to four times to meet the expected results. In case patients still do not respond, appropriate treatment options can be selected depending on the associated medical condition, severity of the symptoms, affordability of the drugs, and accessibility of modern biologics such as omalizumab.

Indexed as

Angioedemaantihistamineautologous serum therapychronic urticariacyclosporinehydroxyzineIndian guidelinesmethotrexatemontelukastomalizumab

Identifiers

PMID29527019
PMCPMC5838750
OpenAlexW2789560611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.